A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic non-small cell lung cancer and other solid tumors.

Trial Details

NCT ID
NCT07232420
Phase
PHASE1
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BL-M24D1
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Voluntarily sign the informed consent form and comply with the protocol requirements;
  • Gender unrestricted;
  • Age: ≥18 years and ≤75 years (Phase Ia); ≥18 years (Phase Ib);
  • Expected survival time ≥3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →